טוען...
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
The FLT3 inhibitor gilteritinib has clinical activity in patients with FLT3‐mutated (FLT3 (mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML). The impact of FLT3 mutation clearance and the achievement of composite complete remission (CRc) and complete remission/complete remission with par...
שמור ב:
| הוצא לאור ב: | Cancer Med |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7897940/ https://ncbi.nlm.nih.gov/pubmed/33340276 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3652 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|